151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Announces Q2 2026 Financial Results and Provides Business Update
Changes in Board, Management or Compensation
CytomX Therapeutics Approves 2015 Plan Amendment for 6.5M Shares
Amendment No. 4 to Collaboration Agreement with Regeneron Executed
Announces Q1 2026 Financial Results and Provides Business Update
CytomX Therapeutics Enters Underwriting Agreement for 45.99M Shares
Announces 2025 Financial Results and Provides Business Update
Announces Third Quarter 2025 Financial Results and Provides Business Update
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload